Functional Association of Cyclophilin A with HIV-1 Virions

var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); ion" CONTENT="Thali et al report that viral particles formed by HIV-1 Gag polyprotein p55(gag) contain significant amounts of cyclophilin A. Sequences in the capsid domain of p55(gag) are both necessary and adequate for the virion-association of cyclophilin A. Cyclosporin A, as well as SDZ NIM811 ([Melle- 4]cyclosporin)--a non-immun"> Functional Association of Cyclophilin A with HIV-1 Virions < > // var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); > < > // var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); >

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Functional Association of Cyclophilin A with HIV-1 Virions

Nature (11/24/94) Vol. 372, No. 6504, P. 363
Thali, Markus; Bukovsky, Anatoly; Kondo, Eisaku et al

Thali et al report that viral particles formed by HIV-1 Gag polyprotein p55(gag) contain significant amounts of cyclophilin A. Sequences in the capsid domain of p55(gag) are both necessary and adequate for the virion-association of cyclophilin A. Cyclosporin A, as well as SDZ NIM811 ([Melle- 4]cyclosporin)--a non-immunosuppressive analogue of cyclosporin A, inhibited the association of cyclophilin A with HIV-1 virions in a dose-dependent manner. Drug-induced reductions in virion-associated cyclophilin A levels were accompanied by reductions in virion infectivity, which suggests that the correlation is functionally relevant. In addition, SDZ NIM811 inhibited the replication of HIV-1 but was inactive against SIV(MAC), a primate version of HIV which does not incorporate cyclophilin A.

941219
AD942262

Copyright © 1994 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .